Results 231 to 240 of about 245,199 (308)

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won   +11 more
wiley   +1 more source

Primary vitreoretinal lymphoma: diagnostic and therapeutic insights from a Slovenian population-based study. [PDF]

open access: yesInt J Retina Vitreous
Vrabič N   +8 more
europepmc   +1 more source

Ulcerated nodules in a sporotrichoid distribution. [PDF]

open access: yes, 2019
de Feraudy, Sebastien   +5 more
core  

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy